QSAR analysis of Δ8-THC analogues: Relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency

Journal of Medicinal Chemistry

Volumn 43, Issue 1, 2000, Pages 59-70

  Keimowitz, Alison R ^a   Martin, Billy R ^b   Razdan, Raj K ^c   Crocker, Peter J ^c   Mascarella, S Wayne ^a   Thomas, Brian F ^a  

^a RTI INTERNATIONAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ORGANIX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1,1 DIMETHYLHEPTYL) DELTA8 TETRAHYDROCANNABINOL; DELTA8 TETRAHYDROCANNABINOL DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONFORMATIONAL TRANSITION; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR AFFINITY;

ANIMALS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RATS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; REGRESSION ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROCANNABINOL;

EID: 0034642492     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9902281     Document Type: Article

References (45)

1. Devane, W. A.; Dysarz, F. A.; Johnson, M. R.; Melvin, L. S.; Hewlett, A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 1988, 34, 605-613.
2. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365, 61-65.
3. Howlett, A. C.; Johnson, M. R.; Melvin, L. S.; Milne, G. M. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 1988, 33, 297-302.
4. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346, 561-564.
5. Deadwyler, S. A.; Hampson, R. E.; Mu, J.; Whyte, A.; Childers, S. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther. 1995, 273, 734-743.
6. Mackie, K.; Hille, B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3825-3829.
7. Mackie, K.; Lai, Y.; Westenbroek, R.; Mitchell, R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 1995, 15, 6552-6561.
8. Compton, D. R.; Rice, K. C.; De Costa, B. R.; Razdan, R. K.; Melvin, L. S.; Johnson, M. R.; Martin, B. R. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 1993, 265, 218-226.
9. Razdan, R. K. Structure-activity relationships in cannabinoids. Pharmacol. Rev. 1986, 38, 75-149.
10. Compton, D. R.; Aceto, M. D.; Lowe, J.; Martin, B. R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 1996, 277, 586-594.
11. Mansbach, R. S.; Rovetti, C. C.; Winston, E. N.; Lowe, J. A. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berlin) 1996, 124, 315-322.
12. Herkenham, M.; Lynn, A. B.; Little, M. D.; Johnson, M. R.; Melvin, L. S.; de Costa, B. R.; Rice, K. C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 1932-1936.
13. Jansen, E. M.; Haycock, D. A.; Ward, S. J.; Seybold, V. S. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res. 1992, 575, 93-102.
14. Felder, C. C.; Joyce, K. E.; Briley, E. M.; Glass, M.; Mackie, K. P.; Fahey, K. J.; Cullinan, G. J.; Hunden, D. C.; Johnson, D. W.; Chaney, M. O.; Koppel, G. A.; Brownstein, M. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. 1998, 284, 291-297.
15. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946-1949.
16. Rinaldi-Carmona, M.; Barth, F.; Heaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Neliat, G.; Caput, D.; et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994, 350, 240-244.
17. Shire, D.; Calandra, B.; Delpech, M.; Dumont, X.; Kaghad, M.; Le Fur, G.; Caput, D.; Ferrara, P. Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J. Biol. Chem. 1996, 271, 6941-6946.
18. Reggio, P. H.; McGaughey, G. B.; Odear, D. F.; Seltzman, H. H.; Compton, D. R.; Martin, B. R. A rational search for the separation of psychoactivity and analgesia in cannabinoids. Pharmacol. Biochem. Behav. 1991, 40, 479-486.
19. Reggio, P. H.; Panu, A. M.; Miles, S. Characterization of a region of steric interference at the cannabinoid receptor using the active analogue approach. J. Med. Chem. 1993, 36, 1761-1771.
20. Reggio, P. H.; Bramblett, R. D.; Yuknavich, H.; Seltzman, H. H.; Fleming, D. N.; Fernando, S. R.; Stevenson, L. A.; Pertwee, R. G. The design, synthesis and testing of desoxy-CBD: further evidence for a region of steric interference at the cannabinoid receptor. Life Sci. 1995, 56, 2025-2032.
21. Semus, S. F.; Martin, B. R. A computergraphic investigation into the pharmacological role of the THC-cannabinoid phenolic moiety. Life Sci. 1990, 46, 1781-1785.
22. Shim, J. Y.; Collantes, E. R.; Welsh, W. J.; Subramaniam, B.; Howlett, A. C.; Eissenstat, M. A.; Ward, S. J. Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (Aminoalkyl)indoles using comparative molecular field analysis. J. Med. Chem. 1998, 41, 4521-4532.
23. Thomas, B. F.; Compton, D. R.; Martin, B. R.; Semus, S. F. Modeling the cannabinoid receptor: a three-dimensional quantitative structure-activity analysis. Mol. Pharmacol. 1991, 40, 656-665.
24. Thomas, B. F.; Adams, I. B.; Mascarella, S. W.; Martin, B. R.; Razdan, R. K. Structure-activity analysis of anandamide analogues: relationship to a cannabinoid pharmacophore. J. Med. Chem. 1996, 39, 471-479.
25. Tong, W.; Collantes, E. R.; Welsh, W. J.; Berglund, B. A.; Howlett, A. C. Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis. J. Med. Chem. 1998, 41, 4207-4215.
26. Xie, X. Q.; Eissenstat, M.; Makriyannis, A. Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids. Life Sci. 1995, 56, 1963-1970.
27. Martin, B. R.; Compton, D. R.; Semus, S. F.; Lin, S.; Marciniak, G.; Grzybowska, J.; Charalambous, A.; Makriyannis, A. Pharmacological evaluation of iodo and nitro analogues of delta 8-THC and delta 9-THC. Pharmacol. Biochem. Behav. 1993, 46, 295-301.
28. Adams, R. Marijuana. Harvey Lectures 1942, 37, 168-197.
29. Winn, M.; Arendsen, D.; Dodge, P.; Dren, A.; Dunnigan, D.; Hallas, R.; Hwang, K.; Kyncl, J.; Lee, Y. H.; Plotnikoff, N.; Young, P.; Zaugg, H. Drugs derived from cannabinoids. 5. delta-6a,10a-Tetrahydrocannabinol and heterocyclic analogues containing aromatic side chains. J. Med. Chem. 1976, 19, 461-471.
30. Martin, B. R.; Kallman, M. J.; Kaempf, G. F.; Harris, L. S.; Dewey, W. L.; Razdan, R. K. Pharmacological potency of R- and S-3′-hydroxy-delta9-tetrahydrocannabinol: additional structural requirement for cannabinoid activity. Pharmacol. Biochem. Behav. 1984, 21, 61-65.
31. Papahatjis, D. P.; Kourouli, T.; Abadji, V.; Goutopoulos, A.; Makriyannis, A. Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1′-substituted delta 8-tetrahydrocannabinols. J. Med. Chem. 1998, 41, 1195-1200.
32. Martin, B. R.; Compton, D. R.; Prescott, W. R.; Barrett, R. L.; Razdan, R. K. Pharmacological evaluation of dimethylheptyl analogues of delta 9-THC: reassessment of the putative three-point cannabinoid-receptor interaction. Drug Alcohol Depend. 1995, 37, 231-240.
33. Busch-Petersen, J.; Hill, W. A.; Fan, P.; Khanolkar, A.; Xie, X. Q.; Tius, M. A.; Makriyannis, A. Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogues. J. Med. Chem. 1996, 39, 3790-3796.
34. Martin, B. R.; Compton, D. R.; Thomas, B. F.; Prescott, W. R.; Little, P. J.; Razdan, R. K.; Johnson, M. R.; Melvin, L. S.; Mechoulam, R.; Ward, S. J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogues. Pharmacol. Biochem. Behav. 1991, 40, 471-478.
35. Schmelzer, S.; Greenidge, P.; Kovar, K. A.; Schulze-Alexandru, M.; Folkers, G. Structure-activity relationships of cannabinoids: a joint CoMFA and pseudoreceptor modelling study. J. Comput.-Aided Mol. Des. 1997, 11, 278-292.
36. Nicklaus, M. C.; Wang, S.; Driscoll, J. S.; Milne, G. W. Conformational changes of small molecules binding to proteins. Bioorg. Med. Chem. 1995, 3, 411-428.
37. Martin, B. R.; Jefferson, R.; Winckler, R.; Wiley: J. L.; Huffman, J. W.; Crocker, P. J.; Saha, B.; Razdan, R. K. Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists. J. Pharmacol. Exp. Ther. 1999, 290, 1065-1079.
38. Marshall, G. R.; Barry, C. D.; Bosshard, H. E.; Dammkoehler, R. A.; Dunn, D. A. The Conformational Parameter in Drug Design: The Active Analogue Approach. In Computer-Assisted Drug Design; Olson, E. C., Christoffersen, R. E., Eds.; American Chemical Society: Washington, DC, 1979; p 619.
39. Rich, M. R. Conformational analysis of arachidonic and related fatty acids using molecular dynamics simulations. Biochim. Biophys. Acta 1993, 1178, 87-96.
40. Altomare, C.; Cellamare, S.; Carotti, A.; Casini, G.; Ferappi, M.; Gavuzzo, E.; Mazza, F.; Carrupt, P. T.; Gaillard, P.; Testa, B. X-ray crystal structure, partitioning behavior, and molecular modeling study of piracetam-type nootropics: insights into the pharmacophore. J. Med. Chem. 1995, 38, 170-179.
41. Nicklaus, M. C.; Milne, G. W.; Burke, T. R., Jr. QSAR of conformationally flexible molecules: comparative molecular field analysis of protein-tyrosine kinase inhibitors. J. Comput.-Aided Mol. Des. 1992, 6, 487-504.
42. Xie, X. Q.; Yang, D. P.; Melvin, L. S.; Makriyannis, A. Conformational analysis of the prototype nonclassical cannabinoid CP-47,497, using 2D NMR and computer molecular modeling. J. Med. Chem. 1994, 37, 1418-1426.
43. Martel, P.; Makriyannis, A.; Mavromoustakos, T.; Kelly, K.; Jeffrey, K. R. Topography of tetrahydrocannabinol in model membranes using neutron diffraction. Biochim. Biophys. Acta 1993, 1151, 51-58.
44. Razdan, R. K.; Haldean, C. D. Drugs derived from cannabinoids. 6. Synthesis of Cyclic analogues of dimethylheptylpyran. J. Med. Chem. 1976, 19, 719-721.
45. Seltzman, H. H.; Setzer, S. R.; Williams, D. L.; Demian, I.; Wyrick, C.; Pitt, C. G. Syntheses of cannabinoid radioligands and haptens for use in radioimmunoassay and receptor site studies. In Marihuana 84: Proceedings of the Oxford Symposium on Cannabis; Harvey, D. J., Ed.; IRL Press: Oxford, England, 1984; pp 183-189.